Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain

Open access

Abstract

Amyloid-beta (Aβ) plays a key role in the pathogenesis of Alzheimer’s disease (AD), but little is known about the proteoforms present in AD brain. We used high-resolution mass spectrometry to analyze intact Aβ from soluble aggregates and insoluble material in brains of six cases with severe dementia and pathologically confirmed AD. The soluble aggregates are especially relevant because they are believed to be the most toxic form of Aβ. We found a diversity of Aβ peptides, with 26 unique proteoforms including various N- and C-terminal truncations. N- and C-terminal truncations comprised 73% and 30%, respectively, of the total Aβ proteoforms detected. The Aβ proteoforms segregated between the soluble and more insoluble aggregates with N-terminal truncations predominating in the insoluble material and C- terminal truncations segregating into the soluble aggregates. In contrast, canonical Aβ comprised the minority of the identified proteoforms (15.3%) and did not distinguish between the soluble and more insoluble aggregates. The relative abundance of many truncated Aβ proteoforms did not correlate with post-mortem interval, suggesting they are not artefacts. This heterogeneity of Aβ proteoforms deepens our understanding of AD and offers many new avenues for investigation into pathological mechanisms of the disease, with implications for therapeutic development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-017-10422-x

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Isolation and comparison of Aβ proteoforms from human AD brain. Workflow for isolation of endogenous Aβ proteoforms. Cortical tissue was dounce homogenized with sub-critical micelle concentration of CHAPS followed by differential ultracentrifugation, anti-Aβ dual antibody immunoprecipitation, and elution in neat formic acid. Immunoprecipitated Aβ proteoforms in the HMW soluble aggregates fractions and more insoluble fractions were precipitated and purified from undigested non-Aβ proteins using C8 TopTips and analyzed by nLC-MS/MS. RCF, relative centrifugal force; Sol., soluble; LMW, low molecular weight; HMW, high molecular weight; IP, immunoprecipitation; pptn., precipitation; SPE, solid phase extraction.
Figure 1 Isolation and comparison of Aβ proteoforms from human AD brain. Workflow for isolation of endogenous Aβ proteoforms. Cortical tissue was dounce homogenized with sub-critical micelle concentration of CHAPS followed by differential ultracentrifugation, anti-Aβ dual antibody immunoprecipitation, and elution in neat formic acid. Immunoprecipitated Aβ proteoforms in the HMW soluble aggregates fractions and more insoluble fractions were precipitated and purified from undigested non-Aβ proteins using C8 TopTips and analyzed by nLC-MS/MS. RCF, relative centrifugal force; Sol., soluble; LMW, low molecular weight; HMW, high molecular weight; IP, immunoprecipitation; pptn., precipitation; SPE, solid phase extraction.CC BY · PubMed Central
Figure 2 Heterogeneity of Aβ proteoforms in the human Alzheimer’s disease brain. (A) Top: full protein sequence of amyloid precursor protein with Aβ1–42 sequence highlighted (grey). Left: Identified Aβ proteoform sequence names, with blue bars representing the alignment with canonical Aβ. Right: Heatmap and quantification of the log2 relative intensity of each Aβ proteoform for each of the six severe Alzheimer’s disease brain samples in the soluble aggregate and more insoluble fractions. Far right: Peptide score, indicated confidence of peptide identification38. (B) Frequency of Aβ proteoform amino acid start positions identified in CDR3 cohort; 1 = D, aspartic acid. (C) Frequency of Aβ proteoform amino acid end positions identified in CDR3 cohort; 42 = A, alanine. (D) Frequency of Aβ proteoform lengths identified in CDR3 cohort. Pt., Participant; HMW, high molecular weight; N.D., not detected; Ox., Oxidation; Pyro., Pyro-glutamate; Amm., ammonium ion.
Figure 2 Heterogeneity of Aβ proteoforms in the human Alzheimer’s disease brain. (A) Top: full protein sequence of amyloid precursor protein with Aβ1–42 sequence highlighted (grey). Left: Identified Aβ proteoform sequence names, with blue bars representing the alignment with canonical Aβ. Right: Heatmap and quantification of the log2 relative intensity of each Aβ proteoform for each of the six severe Alzheimer’s disease brain samples in the soluble aggregate and more insoluble fractions. Far right: Peptide score, indicated confidence of peptide identification38. (B) Frequency of Aβ proteoform amino acid start positions identified in CDR3 cohort; 1 = D, aspartic acid. (C) Frequency of Aβ proteoform amino acid end positions identified in CDR3 cohort; 42 = A, alanine. (D) Frequency of Aβ proteoform lengths identified in CDR3 cohort. Pt., Participant; HMW, high molecular weight; N.D., not detected; Ox., Oxidation; Pyro., Pyro-glutamate; Amm., ammonium ion.CC BY · PubMed Central
Figure 3 Mass spectrometry of Aβ proteoforms from human AD brain. (A) nano-Liquid chromatography-tandem mass spectrometry (nLC-MS/MS) spectrum for undigested, full-length Aβp11–42. Each peak represents an ion fragmented from Aβp11–42, with peaks labeled ‘b’ representing N-terminal fragment ions and peaks labeled ‘y’ representing C-terminal fragment ions. The numbers indicate measured mass-charge ratio (m/z). The single letter amino acid code across the top indicates the de novo sequence identified by mass spectrometry, which matches the amyloid precursor protein sequence corresponding to Aβp11–42. The line breaks between amino acids indicate a cleavage of the amide bond between two adjacent amino acids producing fragment ions. The lines below each amino acid indicate a detected ‘b’ ion, and lines above indicate a detected ‘y’ ion. Inset: isotopic envelope for the +4 charged, full-length Aβp11–42; the peaks are spaced 0.25 daltons apart at z = +4 because the naturally occurring isotopes (e.g. 13C and 15N) differ by 1 dalton. For the +4 ion, the observed m/z was 829.9551 (theoretical m/z = 829.9523), which was 3.4 parts-per-million (ppm) error from the theoretical mass of Aβp11–42. (B) Spectrum for full length Aβ4–42. For the +5 ion, the observed m/z was 840.2427 (theoretical m/z = 840.2399), which was 3.3 ppm error from the theoretical mass of Aβ4–42.
Figure 3 Mass spectrometry of Aβ proteoforms from human AD brain. (A) nano-Liquid chromatography-tandem mass spectrometry (nLC-MS/MS) spectrum for undigested, full-length Aβp11–42. Each peak represents an ion fragmented from Aβp11–42, with peaks labeled ‘b’ representing N-terminal fragment ions and peaks labeled ‘y’ representing C-terminal fragment ions. The numbers indicate measured mass-charge ratio (m/z). The single letter amino acid code across the top indicates the de novo sequence identified by mass spectrometry, which matches the amyloid precursor protein sequence corresponding to Aβp11–42. The line breaks between amino acids indicate a cleavage of the amide bond between two adjacent amino acids producing fragment ions. The lines below each amino acid indicate a detected ‘b’ ion, and lines above indicate a detected ‘y’ ion. Inset: isotopic envelope for the +4 charged, full-length Aβp11–42; the peaks are spaced 0.25 daltons apart at z = +4 because the naturally occurring isotopes (e.g. 13C and 15N) differ by 1 dalton. For the +4 ion, the observed m/z was 829.9551 (theoretical m/z = 829.9523), which was 3.4 parts-per-million (ppm) error from the theoretical mass of Aβp11–42. (B) Spectrum for full length Aβ4–42. For the +5 ion, the observed m/z was 840.2427 (theoretical m/z = 840.2399), which was 3.3 ppm error from the theoretical mass of Aβ4–42.CC BY · PubMed Central
Figure 4 Determination of significant differentially expressed Aβ proteoforms. Logarithmic ratios of soluble versus insoluble fractions are plotted against the negative logarithmic q-values (q is a false discovery rate corrected p-value, where q ≤ 0.05 is considered statistically significant; above horizontal line) of the hierarchical linear model with replicates nested within participants and participants treated as random effects to test the fixed effect difference between soluble and insoluble aggregates. Vertical lines designate the logarithmic ratio indicating ±2-fold change. All Aβ proteoforms are listed in Supplementary Table 3 with their respective q-values and log2 fold change. Ox., Oxidation; Amm, ammonium ion; M, methionine; A, alanine.
Figure 4 Determination of significant differentially expressed Aβ proteoforms. Logarithmic ratios of soluble versus insoluble fractions are plotted against the negative logarithmic q-values (q is a false discovery rate corrected p-value, where q ≤ 0.05 is considered statistically significant; above horizontal line) of the hierarchical linear model with replicates nested within participants and participants treated as random effects to test the fixed effect difference between soluble and insoluble aggregates. Vertical lines designate the logarithmic ratio indicating ±2-fold change. All Aβ proteoforms are listed in Supplementary Table 3 with their respective q-values and log2 fold change. Ox., Oxidation; Amm, ammonium ion; M, methionine; A, alanine.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 164

Metadata

Authors
Wildburger, N. C., Esparza, T. J., LeDuc, R. D., Fellers, R. T., Thomas, P. M., Cairns, N. J., Kelleher, N. L., Bateman, R. J., & Brody, D. L.
Affiliations
  • Washington University in St. Louis (US)
  • Northwestern University (US)
Corresponding author
  • Wildburger, Norelle C.
  • Brody, David L.
Venue
Scientific Reports
Published
2017-08-25
Volume
7
Issue
1
Pages
9520-9520
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2745586739
Cited by
164
References
46
Citations by year
2026: 9 · 2025: 14 · 2024: 11 · 2023: 18 · 2022: 17 · 2021: 28 · 2020: 30 · 2019: 16 · 2018: 18 · 2017: 2
FWCI
13.34
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • BrightFocus Foundation
  • Cure Alzheimer's Fund
  • Hope Center for Neurological Disorders
  • National Institutes of Health (NIH-R01, AG05681, GM108569)
  • Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University in St. Louis
  • National Institute on Aging (P50AG005681, P01AG003991)
  • National Institute of General Medical Sciences (P41GM108569, GM108569)
  • National Institute of Neurological Disorders and Stroke (R01NS065069, R01NS065667)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
amyloid-beta, proteoforms, Alzheimer's disease, N-terminal truncation, C-terminal truncation, postmortem interval, neuropathology
MeSH terms
Alzheimer Disease, Amino Acid Sequence, Brain, Chromatography, Liquid, Humans, Solubility, Amyloid beta-Peptides, Proteomics, Tandem Mass Spectrometry, Plaque, Amyloid, Protein Aggregation, Pathological, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain. https://app.cochat.ai/papers/10.1038/s41598-017-10422-x
The paper
Wildburger, N. C., Esparza, T. J., LeDuc, R. D., Fellers, R. T., Thomas, P. M., Cairns, N. J., Kelleher, N. L., Bateman, R. J., & Brody, D. L. (2017). Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain. Scientific Reports. https://doi.org/10.1038/s41598-017-10422-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.